88 Businessexcellence September 07 What began in 1977 as a side retail business has today become a leading formulator and supplier of nutritional supplements worth over $65 million with nearly 400 products. Jarrow Formulas, Inc. based in Los Angeles, sells its vitamins, minerals, probiotics, herbal concentrates, and other products in the US and in more than 20 countries throughout Europe, Asia, and Latin America. Although not approved by the Federal Drug Administration, Jarrow’s products are widely regarded for their purity, potency, and affordability. Sound scientifi c research is at the heart of its products. Jarrow’s employees remain actively involved in clinical studies and work alongside researchers from universities around the world to develop new products. In addition, the company opened a separate GMP-certifi ed contract manufacturer, Jarrow Industries, Inc. based in Santa Fe Springs, California, to produce its own products and ensure high quality. Jarrow introduced nearly 50 innovative formulas in 2004, including Ester Carnitine GPLC, for cardiovascular and peripheral circulatory health; Flax Essence, a fl ax lignan formulation for hormonal balance, cellular support, and prostate health; and BroccoMax with SGS (sulforaphane glucosinolate), an anti-cancer compound extracted from broccoli seeds. Additionally, Jarrow Formulas recently launched an exclusive line of premium pomegranate dietary supplements, such as PomGuard, which offers greater bioavailability than other pomegranate supplements because it contains specially fermented and dried pomegranate juice. The results of a clinical trial investigating the effects of Jarrow’s Q-absorb, which is an enhancedabsorption CoQ10 formula, on chronic heart failure patients were published in European Heart Journal’s August 2006 issue. Italian scientists from the Lancisi Heart Institute and the University of Ancona measured the effects of 300 mg per day of Q-absorb on the cardiovascular functional capacity of 23 heart patients. Measurements included endothelial-dependent vasodilation as measured by ultrasound brachial artery reactivity test, plasma ubiquinone, and other important cardiovascular biochemical parameters. The randomized, placebo-controlled, doubleblind, crossover clinical trial results proved the effi cacy of the product as demonstrated by improved functional capacity, improved endothelial-dependent vasodilation, and the tripling of plasma coenzyme Q10 levels. “This study adds signifi cantly to a growing body of evidence that CoQ10 supplementation may be an effi cacious complementary method for improving cardiac function in heart failure patients,” said Kevin Connolly, PhD, director of scientifi c affairs and product development at Jarrow Formulas. “It also validates that our Q-Absorb is a successful natural delivery system for CoQ10, an antioxidant that typically exhibits poor bioavailability. Prior to this study, we had invested several years into the development and study of Q-absorb, and we are excited to see it perform so successfully in patients.” This year, Jarrow celebrates its 30th anniversary, and along with its steadily increasing profi ts it has an impressive list of awards and acknowledgments. For instance, Nutrition Business Journal awarded Jarrow its Business Achievement Award in the Investment in Jarrow Formulas, Inc. has created a business as healthy as its products. Kate Sawyer reports Ahealthybusiness
October 07 Businessexcellence 89 Science and Research category, for its ongoing CoQ-10 clinical studies; the journal also awarded its Product Merit Award for two of Jarrow’s new products, MK-7 (Menaquinone-7), an enhanced bioactive form of vitamin K and Pressure Optimizer, as well as a supplement that supports proper blood pressure regulation. In addition, Jarrow brought home a 2005 Vity Award for Bone-Up, the fourth consecutive year that Jarrow Formulas won in the Bone Support category. Most recently, Jarrow received Frost & Sullivan’s 2006 Product Line Leadership of the Year Award for offering the most comprehensive and innovative product portfolio across all health categories in dietary supplements. Frost & Sullivan presents this award each year to a deserving company that has demonstrated the most insight into customer needs and product demands. Jarrow was chosen for its proven ability to offer competitive products while answering the call for price, performance, and feature points by the market. “We have the premier product development team in the industry,” said Mark Becker, director advertising/communications for Jarrow Formulas, in response to the award. “Jarrow Rogovin (president), Sid Shastri, MSc. (VP, product development), Peilin Guo, MS, RD (VP, functional foods), Dallas Clouatre, PhD (consultant), and Kevin Connolly, PhD (director, scientifi c affairs) understand today’s pressing health issues. And they work very closely with researchers and leaders in the scientifi c community worldwide to bring the most innovative products to the marketplace.” JarrowFormulas Indena is a leading company dedicated to the identifi cation, development and production of active principles derived from medicinal plants, serving the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, employs around 700 employees, including 10 percent dedicated to full-time research. Indena manages cultivation, manufacturing, and distribution operations in over 40 countries throughout the world. Indena USA, Inc.